{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:34Z","timestamp":1792511494765,"version":"4.5.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic graft-versus-host disease (cGVHD)-related serositis is rare, and primarily presents as polyserous effusions. The low incidence and differential diagnosis impose significant challenges to the prompt diagnosis and the effective treatment of the disease. Here we report the diagnosis and treatment of a 57-year-old woman who experienced recurrent steroid-refractory cGVHD-related serositis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We thus added baricitinib, a specific JAK1\/2 inhibitor, into the treatment regimen for the recurrent disease. The patient\u2019s clinical symptoms and effusions were effectively relieved. Currently, no recurrence of serositis and significant adverse events were observed. The utilization of baricitinib might emerge as a novel promising therapeutic option for the treatment of steroid-refractory GVHD following allo-HSCT.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1546599","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:41:19Z","timestamp":1743486079000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Diagnosis and successful treatment of a rare case of steroid-refractory chronic graft-vs-host disease-related serositis"],"prefix":"10.3389","volume":"16","author":[{"given":"Zilin","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.105","article-title":"Chronic GvHD-associated serositis and pericarditis","volume":"50","author":"Leonard","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1541-z","article-title":"Large pericardial effusion as a life-threatening complication after hematopoietic stem cell transplantation-association with chronic GVHD in late-onset adult patients","volume":"91","author":"Liu","year":"2012","journal-title":"Ann Hematol"},{"key":"B3","article-title":"Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease","volume":"17","author":"Seber","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2015.169.issue-5","article-title":"Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation","volume":"169","author":"Liu","year":"2015","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24435","article-title":"Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Modi","year":"2016","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"579A","DOI":"10.1016\/j.chest.2016.08.668","article-title":"A review of chronic graft vs host disease-associated serositis: what we know and don\u2019t","volume":"150","author":"Ballal","year":"2016","journal-title":"CHEST"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05643-w","article-title":"Isolated massive pleural effusion as a manifestation of chronic graft versus host disease successfully treated with corticosteroid","volume":"103","author":"Masuda","year":"2024","journal-title":"Ann Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V57.2.267.267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease","volume":"32","author":"Choi","year":"2018","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-140392","article-title":"Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): preliminary analysis results of a phase 1\/2 study","volume":"136","author":"Holtzman","year":"2020","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab599","article-title":"Successful treatment of joint and fascial chronic graft-versus-host disease with baricitinib","volume":"61","author":"Shimizu","year":"2021","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1546599\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:41:37Z","timestamp":1743486097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1546599\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2025.1546599"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1546599","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"1546599"}}